After it drops 13.5% in a day, is it time I bought this S&P 500 growth stock?

The Eli Lilly (NYSE:LLY) share price fell by double digits in the S&P 500 today, leaving this Fool debating whether he should reinvest.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Eli Lilly (NYSE: LLY) has been one of the standout stocks in the S&P 500 in recent years. It’s up 597% in five years and a whopping 1,090% over the past decade. That’s mightily impressive for a mature pharma firm.

In the past couple of years, the company’s upwards trajectory was given a turbo-boost by its blockbuster GLP-1 drugs Mounjaro and Zepbound. The latter was approved late last year specifically for weight loss, which is a market that is expected to drive massive sales long into the future.

Today (30 October), however, the Eli Lilly share price slumped 13% after the company’s third-quarter results disappointed Wall Street. This rare stumble leaves me wondering if I should pick up some shares while they’re down.

Should you invest £1,000 in BT right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BT made the list?

See the 6 stocks

Created with Highcharts 11.4.3Eli Lilly PriceZoom1M3M6MYTD1Y5Y10YALL30 Oct 201930 Oct 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

What happened

Heading into the quarter, analysts expected $12.1bn in revenue and adjusted earnings per share (EPS) of $1.47. But the company reported revenue of $11.4bn and adjusted EPS of $1.18. So there was an earnings miss and the firm lowered its full-year EPS guidance, to $13.02-$13.52 from $16.10-$16.60.

Still, the quarter didn’t look bad to me. Far from it. Revenue increased 20% year on year, driven by growth from Mounjaro and Zepbound. Excluding $1.42bn in Q3 2023 from the sale of rights for its olanzapine (antipsychotics) portfolio, revenue surged 42%!

Outside of weight-loss drugs, there was impressive 17% revenue growth in oncology, immunology, and neuroscience. This was a very strong quarter, despite what the share price drop might suggest.

Expanding markets

Eli Lilly’s market cap is now $748bn, which makes it one of the largest companies in the world. But if the likes of Apple, Amazon, and Microsoft have taught us anything, it’s that the already big can carry on getting bigger, as long as they keep finding new avenues of growth.

In this regard, I’m bullish on the company’s prospects. According to Morgan Stanley, the global market for blockbuster obesity drugs could increase by more than 15-fold by 2030. This is due to them potentially spreading beyond weight loss to treat a range of diseases.

For example, early research suggests that these GLP-1 drugs may have neuroprotective effects and could potentially slow the progression of Alzheimer’s disease. They also reportedly reduce alcohol intake, so could potentially treat addiction.

Of course, it’s early days to know any of this for sure. And there could be some negative long-term effects with these weight-loss drugs that we don’t know about. That’s a key risk, as is competition from market leader Novo Nordisk, the maker of Wegovy and Ozempic.

Also, due to high demand and supply shortages, there are loads of cheaper knock-offs floating about.

Should I rebuy?

I owned Eli Lilly stock a while back. However, I sold after it doubled in a year and the price-to-earnings (P/E) multiple went well above 100.

Currently though, the forward P/E ratio here is 37, falling to 24 by 2027. For a company with such a strong position in multiple massive growth markets — it also recently got an Alzheimer’s drug, donanemab, approved — I don’t think that’s outrageous.

Looking ahead, I reckon Eli Lilly looks likely to become the first $1trn drug company. I’ve put the stock back on my watchlist, with an eye to reinvesting at some point.

Should you buy BT shares today?

Before you decide, please take a moment to review this first.

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has recommended Amazon, Apple, Microsoft, and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Investing For Beginners

Why I’m staying away from the Barclays share price even with a 19% drop

Jon Smith explains why he's cautious right now about the Barclays share price, with the potential for lower revenues from…

Read more »

Investing Articles

2 FTSE 100 and FTSE 250 stocks to consider as stock markets plummet!

Looking for lifeboats as growth-crushing trade tariffs loom? Here are two (including a FTSE 100 gold stock) I think merit…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Watches of Switzerland shares 1 year ago is now worth…

Watches of Switzerland shares have been decimated by Trump’s tariffs on Switzerland. Dr James Fox explores whether this is an…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Investing Articles

Growth stocks are crashing! Here’s what I’m doing now

Our writer shares his thoughts as growth stocks get crushed, as well as a favourite from the Nasdaq that he…

Read more »

Investing Articles

What’s going on with the Nvidia share price now?

The Nvidia share price is tanking. Once the most valuable listed company, Nvidia has seen more than $1trn wiped off…

Read more »

Investing Articles

This FTSE AIM stock has £2.3bn in net cash, and a market cap of £2.4bn!

I love this FTSE AIM stock, but it really hasn’t delivered for me yet. The stock trades with crazily low…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Down 15% in a week! Are these 5 FTSE 100 fallers screaming buys as markets plunge?

Five of Harvey Jones's favourite FTSE 100 stocks all have the same thing in common – they've fallen around 15%…

Read more »